Company research
ARS Pharmaceuticals, Inc.
CIK 1671858Updated Nov 16, 2026
SPRY price & chart
Loading TradingView…
NASDAQ:SPRY on TradingView ↗About the company
ARS Pharma is a biopharmaceutical company developing and commercializing treatments that help at-risk patients and their caregivers treat and prevent severe allergic reactions. The company is commercializing neffy® (epinephrine nasal spray), the only needle-free epinephrine approved by the U.S. Food & Drug Administration, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15 kg) or more. In the European Union, the product is marketed as EURneffy®, the only needle-free epinephrine product authorized by the European Commission, for the emergency treatment of allergic reactions, including anaphylaxis, in adults and children four years of age and older weighing 15 kg or more. The product is also marketed as 优敏速® in China. Leveraging its intranasal technology, ARS Pharma is also developing ARS-2, currently in a Phase 2b clinical trial, as a potential first treatment for acute breakthrough flares of chronic spontaneous urticaria (CSU). For more information, visit www.ars-pharma.com and follow us on LinkedIn.
In the news
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY ↗
Seeking Alpha
ARS Pharmaceuticals: Neffy Is Gaining Traction, But Revenue Growth Needs To Catch Up ↗
Ars Pharmaceuticals targets cash flow breakeven by year-end 2027 as neffy U.S. share surpasses 5% ↗
ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript ↗
SEC disclosures
ARS Pharmaceuticals, Inc. files 8-K: Material Event ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 372,803,000Source | 217,601,000Source | 249,495,000Source | 313,472,000Source | 221,966,000Source | 287,571,000Source | 327,318,000Source | 227,583,000Source | 327,652,000Source | 351,153,000Source | 233,188,000Source | 281,435,000Source |
| Property, Plant and Equipment, NetUSD | 1,209,000Source | 843,000Source | 2,085,000Source | 1,075,000Source | 636,000Source | 2,285,000Source | 1,075,000Source | 616,000Source | 2,465,000Source | 1,029,000Source | 574,000Source | 329,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 14,729,000Source | 7,500,000Source | 13,900,000Source | 12,972,000Source | — | 14,176,000Source | 7,241,000Source | — | 14,452,000Source | 7,371,000Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 59,557,000Source | 39,657,000Source | 8,163,000Source | 51,540,000Source | 36,626,000Source | 24,321,000Source | 39,864,000Source | 56,006,000Source | 41,317,000Source | 50,817,000Source | 70,971,000Source | 210,518,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 36,451,000Source | 773,000Source | 46,839,000Source | 25,126,000Source | — | 28,662,000Source | 9,303,000Source | — | 25,347,000Source | 8,175,000Source | — | — |
| Inventory, NetUSD | 21,427,000Source | 715,000Source | 30,734,000Source | 22,112,000Source | — | 32,038,000Source | 7,270,000Source | — | 31,422,000Source | 5,212,000Source | — | — |
| Assets, CurrentUSD | 338,863,000Source | 208,789,000Source | 211,510,000Source | 281,436,000Source | 220,738,000Source | 245,236,000Source | 303,860,000Source | 226,241,000Source | 284,896,000Source | 334,295,000Source | 231,726,000Source | 277,700,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,421,000Source | 2,677,000Source | 9,137,000Source | 7,442,000Source | 1,994,000Source | 6,788,000Source | 11,560,000Source | 2,609,000Source | 6,194,000Source | 6,886,000Source | 3,366,000Source | 3,319,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,439,000Source | 92,000Source | — | 1,564,000Source | 146,000Source | — | 72,000Source | 198,000Source | — | 37,000Source | 250,000Source | 445,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 225,148,000Source | 16,623,000Source | 236,983,000Source | 121,151,000Source | 6,725,000Source | 226,263,000Source | 98,344,000Source | 3,715,000Source | 213,394,000Source | 94,355,000Source | 2,428,000Source | 8,549,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 10,000Source | 9,000Source |
| Additional Paid in CapitalUSD | 400,931,000Source | 373,868,000Source | 430,202,000Source | 394,485,000Source | 369,487,000Source | 416,615,000Source | 386,137,000Source | 365,577,000Source | 408,726,000Source | 379,873,000Source | 362,004,000Source | 349,408,000Source |
| Retained Earnings (Accumulated Deficit)USD | -253,279,000Source | -173,239,000Source | -417,560,000Source | -202,128,000Source | -154,111,000Source | -355,221,000Source | -157,245,000Source | -141,595,000Source | -294,603,000Source | -123,305,000Source | -131,303,000Source | -76,938,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -7,000Source | 339,000Source | -140,000Source | -46,000Source | -145,000Source | -96,000Source | 72,000Source | -124,000Source | 125,000Source | 220,000Source | 49,000Source | 407,000Source |
| Stockholders' Equity Attributable to ParentUSD | 147,655,000Source | 200,978,000Source | 12,512,000Source | 192,321,000Source | 215,241,000Source | 61,308,000Source | 228,974,000Source | 223,868,000Source | 114,258,000Source | 256,798,000Source | 230,760,000Source | 272,886,000Source |
| Liabilities and EquityUSD | 372,803,000Source | 217,601,000Source | 249,495,000Source | 313,472,000Source | 221,966,000Source | 287,571,000Source | 327,318,000Source | 227,583,000Source | 327,652,000Source | 351,153,000Source | 233,188,000Source | 281,435,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 50,877,000Source | 16,623,000Source | 60,863,000Source | 45,599,000Source | 6,725,000Source | 49,612,000Source | 27,622,000Source | 3,715,000Source | 39,145,000Source | 23,440,000Source | 2,391,000Source | 5,444,000Source |
| Operating Lease, Liability, CurrentUSD | 583,000Source | 102,000Source | — | 589,000Source | 160,000Source | — | 73,000Source | 217,000Source | — | 42,000Source | 237,000Source | 230,000Source |
| Accounts Payable, CurrentUSD | 8,382,000Source | 8,276,000Source | 5,198,000Source | 15,559,000Source | 3,272,000Source | 4,705,000Source | 4,095,000Source | 839,000Source | 5,725,000Source | 9,870,000Source | 759,000Source | 1,659,000Source |
| Operating Lease, Liability, NoncurrentUSD | 949,000Source | 0Source | — | 1,072,000Source | 0Source | — | — | 0Source | — | 0Source | 37,000Source | 251,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 394,000Source | 138,000Source | 112,000Source | 249,000Source |
| Long-term DebtUSD | 96,229,000Source | — | 96,676,000Source | — | — | 96,522,000Source | — | — | 96,374,000Source | — | — | — |
| Short-term InvestmentsUSD | 228,652,000Source | 164,967,000Source | 135,682,000Source | 188,590,000Source | 182,118,000Source | 176,648,000Source | 235,863,000Source | 167,626,000Source | 203,669,000Source | 263,205,000Source | 157,389,000Source | 63,863,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 5,689,000Source | 3,591,000Source | 12,395,000Source | 5,371,000Source | 7,423,000Source | 5,298,000Source | 22,095,000Source | 14,534,000Source | 9,235,000Source | 5,843,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 839,000Source | 1,128,000Source | 17,205,000Source | 8,175,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 294,000Source | 8,449,000Source | 21,986,000Source | 5,945,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -44,946,000Source | -40,742,000Source | -170,866,000Source | 13,548,000Source | -59,266,000Source | -40,078,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 27,791,000Source | 29,064,000Source | 56,768,000Source | -106,101,000Source | -87,180,000Source | -199,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 91,000Source | 339,000Source | 563,000Source | 175,000Source | 199,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 159,000Source | 725,000Source | 104,598,000Source | 72,399,000Source | 6,899,000Source | 190,732,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -16,996,000Source | -10,953,000Source | -9,500,000Source | -20,154,000Source | -139,547,000Source | 150,455,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 59,557,000Source | 39,657,000Source | 8,163,000Source | 51,540,000Source | 24,321,000Source | 39,864,000Source | 41,317,000Source | 50,817,000Source | 70,971,000Source | 210,518,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 2,293,000Source | 0Source | 2,452,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 200,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 3,591,000Source | — | — | — | — | — | 14,534,000Source | 9,235,000Source | 5,843,000Source |
| Amortization of Intangible AssetsUSD | — | — | 200,000Source | 0Source | 300,000Source | 100,000Source | 300,000Source | 100,000Source | 800,000Source | 100,000Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | 79,000Source | 73,000Source | — |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 319,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -140,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 47,284,000Source | 18,456,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -80,000Source | 288,000Source | 0Source | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 2,160,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -51,151,000Source | -19,128,000Source | -62,339,000Source | -44,883,000Source | -60,618,000Source | -33,940,000Source | -171,298,000Source | 7,998,000Source | -54,365,000Source | -34,682,000Source |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 834,000Source |
| Operating Costs and ExpensesUSD | — | — | — | 406,000Source | — | — | — | — | — | 2,066,000Source | 1,796,000Source | — |
| Operating ExpensesUSD | — | — | 85,693,000Source | 23,816,000Source | 95,123,000Source | 63,331,000Source | 82,826,000Source | 45,150,000Source | 263,726,000Source | 92,232,000Source | 67,550,000Source | 36,832,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,041,000Source | 2,620,000Source | -874,000Source | 2,731,000Source | -473,000Source | 3,237,000Source | 8,070,000Source | 11,369,000Source | 13,155,000Source | 974,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 32,501,000Source | 2,068,000Source | 33,658,000Source | 15,717,000Source | 22,681,000Source | 7,973,000Source | 84,278,000Source | 89,149,000Source | 30,000Source | 1,316,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 74,751,000Source | 19,281,000Source | 77,579,000Source | 54,312,000Source | 72,204,000Source | 41,104,000Source | 230,122,000Source | 71,675,000Source | 940,000Source | — |
| Operating Income (Loss)USD | — | — | -53,192,000Source | -21,748,000Source | -61,465,000Source | -47,614,000Source | -60,145,000Source | -37,177,000Source | -179,448,000Source | -3,083,000Source | -67,520,000Source | -35,516,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,041,000Source | 2,620,000Source | -874,000Source | 2,731,000Source | -473,000Source | 3,237,000Source | 8,070,000Source | 11,369,000Source | 13,155,000Source | 974,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -171,378,000Source | 8,286,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -80,000Source | 288,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -51,151,000Source | -19,128,000Source | -62,339,000Source | -44,883,000Source | -60,618,000Source | -33,940,000Source | -171,298,000Source | 7,998,000Source | -54,365,000Source | -34,682,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.52Source | -0.2Source | -0.63Source | -0.46Source | -0.61Source | -0.35Source | -1.74Source | 0.08Source | -0.57Source | -0.87Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.52Source | -0.2Source | -0.63Source | -0.46Source | -0.61Source | -0.35Source | -1.74Source | 0.08Source | -0.57Source | -0.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 98,807,600Source | 97,032,331Source | 99,312,526Source | 98,361,771Source | 99,296,408Source | 98,060,636Source | 98,566,481Source | 96,936,661Source | 95,215,322Source | 39,956,043Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 98,807,600Source | 97,032,331Source | 99,312,526Source | 98,361,771Source | 99,296,408Source | 98,060,636Source | 98,566,481Source | 102,390,828Source | 95,215,322Source | 39,956,043Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 200,000Source | 0Source | 300,000Source | 100,000Source | 300,000Source | 100,000Source | 800,000Source | 100,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -80,000Source | 288,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 397,000Source | 280,000Source | 1,367,000Source | 100,000Source | 100,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -140,000Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 47,284,000Source | 18,456,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -171,372,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 834,000Source |
| Operating Costs and ExpensesUSD | — | — | — | 406,000Source | — | — | — | — | — | 2,066,000Source | 1,796,000Source | — |
| Operating ExpensesUSD | — | — | 85,693,000Source | 23,816,000Source | 95,123,000Source | 63,331,000Source | 82,826,000Source | 45,150,000Source | 263,726,000Source | 92,232,000Source | 67,550,000Source | 36,832,000Source |
| Research and Development ExpenseUSD | — | — | 2,751,000Source | 4,423,000Source | 4,698,000Source | 4,035,000Source | 4,336,000Source | 2,952,000Source | 13,181,000Source | 19,580,000Source | 20,266,000Source | 18,376,000Source |
Filing attachments
spry-ex99_1.htm · 8-K · 2026-11-05
Exhibit 99.1 ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy® neffy U.S. market share reached 5% overall and 9% in field-targeted accounts, supporting the company’s updated targeted provider commercial strategy Reduced SG&A spend reflected in Q3 operating expenses; reaffirm path to cash flow breakeven by year-end 2027 Leadership team strengthened with appointments…
Read attachment ↗spry-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results $26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted provider engagement, significantly reducing total operating expenses for 2H 202…
Read attachment ↗spry-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 total revenue of $22.7 million including neffy U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales force expansion to 148 representatives completed Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout Confer…
Read attachment ↗spry-ex99_2.htm · 8-K · 2026-05-15
EX-99.2 3 spry-ex99_2.htm EX-99.2 May 2026 Corporate Presentation neffy - the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the potential ma…
Read attachment ↗spry-ex99_1.htm · 8-K · 2026-03-09
EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipa…
Read attachment ↗spry-ex99_2.htm · 8-K · 2026-03-09
EX-99.2 3 spry-ex99_2.htm EX-99.2 March 2026 Corporate Presentation neffy - the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the potential …
Read attachment ↗